Skip to main content
Caplight Logo









Taizhou Baiying Biotechnology

Taizhou Baiying Biotechnology

Private
Shanghai, ShanghaiHealthcare & Life Scienceshttps://www.biointron.com

Last Round

Series B

Sep 2, 2022

Total Funding Raised

$92.05M

Company Overview

Biointron is a biotechnology company specializing in recombinant antibody technology and contract research organization (CRO) services aimed at streamlining the antibody discovery process through advanced expression platforms, sequencing, and labeling tools.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract research organizationCROrecombinant antibody expressionantibody discoveryprotein expressionantibody engineeringdrug discovery serviceswet-lab servicesstable cell line developmentbiologics developmentantibody humanizationaffinity maturationVHH antibody discoveryantibody-drug conjugateADCsingle B-cell screeninghybridoma sequencing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Taizhou Baiying Biotechnology Comparables

Compare Taizhou Baiying Biotechnology with similar companies based on industry and business-model similarity.

Taizhou Baiying Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Creative Biolabs
85%
Genovac Antibody Discovery
82%
ProteoGenix
82%

Taizhou Baiying Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 2, 2022
Series AMay 24, 2021
AngelJul 23, 2018

Taizhou Baiying Biotechnology Investors

Notable investors and investment history

Taizhou Baiying Biotechnology investors
InvestorRounds
Jifeng VenturesSeries B
Haitong BankSeries B
Joy CapitalSeries B
Jiangsu Provincial Government Investment FundSeries B
Furong InvestmentSeries A
ALAN Asset ManagementSeries B
Jiangsu Tianyou Investment ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    New platform helps drug developers identify manufacturing problems early.

  • Dec 17, 2025

    Received the 2025 Scientist.com Supplier Performance Recognition Award.

Recent news

Latest coverage and updates

  • launchesJul 27, 2026

    Biointron Biological USA Inc launched RushData platform for AI-driven antibody discovery on Jul 27th '26.

  • attends_eventJul 13, 2026

    Biointron attended event BIO International Convention on Jun 23rd '26.

Taizhou Baiying Biotechnology Filings

Explore SEC and related filing metadata, where available.

Taizhou Baiying Biotechnology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Taizhou Baiying Biotechnology's valuation, stock price, and market status.

Is Taizhou Baiying Biotechnology a public or private company?

Taizhou Baiying Biotechnology is a private company.

What is the current stock price of Taizhou Baiying Biotechnology?

Taizhou Baiying Biotechnology is a private company with no public stock price. No recent secondary market data is available.

How much is Taizhou Baiying Biotechnology worth (valuation)?

Valuation information for Taizhou Baiying Biotechnology is not publicly available.

Can I buy Taizhou Baiying Biotechnology stock?

Taizhou Baiying Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Taizhou Baiying Biotechnology's last funding round?

Taizhou Baiying Biotechnology's most recent funding round was Series B on September 2, 2022.

Who are the main investors in Taizhou Baiying Biotechnology?

Key investors in Taizhou Baiying Biotechnology include Jifeng Ventures, Haitong Bank, CoStone Capital.

Will Taizhou Baiying Biotechnology IPO soon?

No public IPO plans have been announced for Taizhou Baiying Biotechnology.

How can I track Taizhou Baiying Biotechnology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Taizhou Baiying Biotechnology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai, Shanghai
Employee Range42
Year Founded2012
Last FundingSep 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?